Overview
Neumora Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to brain diseases, with a pipeline targeting depression, schizophrenia, and other psychiatric disorders through novel receptor-targeted mechanisms. Their lead asset navacaprant is a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
South San Francisco, USA
Funding
Public · NASDAQ: NRXS
Website
www.neumoratherapeutics.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →